Targeting the Microenvironment in High Grade Serous Ovarian Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Aug 15

PMID 30103384

Citations 29

Authors

Nkechiyere G Nwani

Livia E Sima

Wilberto Nieves-Neira

Daniela Matei

Affiliations

Soon will be listed here.

Abstract

Cancer⁻stroma interactions play a key role in cancer progression and response to standard chemotherapy. Here, we provide a summary of the mechanisms by which the major cellular components of the ovarian cancer (OC) tumor microenvironment (TME) including cancer-associated fibroblasts (CAFs), myeloid, immune, endothelial, and mesothelial cells potentiate cancer progression. High-grade serous ovarian cancer (HGSOC) is characterized by a pro-inflammatory and angiogenic signature. This profile is correlated with clinical outcomes and can be a target for therapy. Accumulation of malignant ascites in the peritoneal cavity allows for secreted factors to fuel paracrine and autocrine circuits that augment cancer cell proliferation and invasiveness. Adhesion of cancer cells to the mesothelial matrix promotes peritoneal tumor dissemination and represents another attractive target to prevent metastasis. The immunosuppressed tumor milieu of HGSOC is permissive for tumor growth and can be modulated therapeutically. Results of emerging preclinical and clinical trials testing TME-modulating therapeutics for the treatment of OC are highlighted.

Citing Articles

YKL40/Integrin β4 Axis Induced by the Interaction between Cancer Cells and Tumor-Associated Macrophages Is Involved in the Progression of High-Grade Serous Ovarian Carcinoma.

Yamanaka K, Koma Y, Urakami S, Takahashi R, Nagamata S, Omori M Int J Mol Sci. 2024; 25(19).

PMID: 39408927 PMC: 11477481. DOI: 10.3390/ijms251910598.

Amphiregulin Downregulates E-cadherin Expression by Activating YAP/Egr-1/Slug Signaling in SKOV3 Human Ovarian Cancer Cells.

Jia Q, Wang H, Bi B, Han X, Jia Y, Zhang L Reprod Sci. 2024; 32(2):404-416.

PMID: 39138796 DOI: 10.1007/s43032-024-01673-x.

Targeted therapy in high grade serous ovarian Cancer: A literature review.

Dinkins K, Barton W, Wheeler L, Smith H, Mythreye K, Arend R Gynecol Oncol Rep. 2024; 54:101450.

PMID: 39092168 PMC: 11292514. DOI: 10.1016/j.gore.2024.101450.

Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.

Battistini C, Kenny H, Zambuto M, Nieddu V, Melocchi V, Decio A Cell Death Dis. 2024; 15(5):370.

PMID: 38806454 PMC: 11133450. DOI: 10.1038/s41419-024-06767-7.

Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.

Licaj M, Mhaidly R, Kieffer Y, Croizer H, Bonneau C, Meng A Nat Commun. 2024; 15(1):1312.

PMID: 38346978 PMC: 10861537. DOI: 10.1038/s41467-024-45595-3.

References

Matei D, Emerson R, Schilder J, Menning N, Baldridge L, Johnson C . Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer. 2008; 113(4):723-32. DOI: 10.1002/cncr.23605. View

Kenny H, Lengyel E . MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009; 8(5):683-8. PMC: 2840625. DOI: 10.4161/cc.8.5.7703. View

Giusti I, Di Francesco M, DAscenzo S, Palmerini M, Macchiarelli G, Carta G . Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior. Cancer Biol Ther. 2018; 19(8):722-734. PMC: 6067870. DOI: 10.1080/15384047.2018.1451286. View

Matei D, Graeber T, Baldwin R, Karlan B, Rao J, Chang D . Gene expression in epithelial ovarian carcinoma. Oncogene. 2002; 21(41):6289-98. DOI: 10.1038/sj.onc.1205785. View

Raab-Westphal S, Marshall J, Goodman S . Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel). 2017; 9(9). PMC: 5615325. DOI: 10.3390/cancers9090110. View

Matei D, Sill M, Lankes H, DeGeest K, Bristow R, Mutch D . Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2010; 29(1):69-75. PMC: 3055861. DOI: 10.1200/JCO.2009.26.7856. View

Holmes D, Zachary I . The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005; 6(2):209. PMC: 551528. DOI: 10.1186/gb-2005-6-2-209. View

Akhurst R . Targeting TGF-β Signaling for Therapeutic Gain. Cold Spring Harb Perspect Biol. 2017; 9(10). PMC: 5630004. DOI: 10.1101/cshperspect.a022301. View

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N . Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015; 17(1):78-89. DOI: 10.1016/S1470-2045(15)00366-6. View

10.

Teng L, Jin K, He K, Zhang J, Wang H, Cao J . Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010; 73(9):449-56. DOI: 10.1016/S1726-4901(10)70097-6. View

11.

Matulonis U, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C . Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009; 27(33):5601-6. PMC: 2792954. DOI: 10.1200/JCO.2009.23.2777. View

12.

Zhang M, Liu T, Xia B, Yang C, Hou S, Xie W . Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2017; 28(2):323-331. DOI: 10.1097/IGC.0000000000001171. View

13.

Barton D, Cai A, Wendt K, Young M, Gamero A, De Cesare S . Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 1998; 3(9):1579-86. View

14.

Gao Y, Shan N, Zhao C, Wang Y, Xu F, Li J . LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells. Int J Clin Exp Pathol. 2015; 8(5):4923-32. PMC: 4503057. View

15.

Gopinathan G, Milagre C, Pearce O, Reynolds L, Hodivala-Dilke K, Leinster D . Interleukin-6 Stimulates Defective Angiogenesis. Cancer Res. 2015; 75(15):3098-107. PMC: 4527186. DOI: 10.1158/0008-5472.CAN-15-1227. View

16.

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

17.

Soffietti R, Trevisan E, Ruda R . What have we learned from trials on antiangiogenic agents in glioblastoma?. Expert Rev Neurother. 2014; 14(1):1-3. DOI: 10.1586/14737175.2014.873277. View

18.

Engblom C, Pfirschke C, Pittet M . The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016; 16(7):447-62. DOI: 10.1038/nrc.2016.54. View

19.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1):9-22. View

20.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View